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Hepatitis C virus (HCV) belongs to the Hepacivirus genus and is genetically
heterogeneous, with seven major genotypes further divided into several recognized
subtypes. HCV origin was previously dated in a range between ∼200 and 1000 years
ago. Hepaciviruses have been identified in several domestic and wild mammals, the
largest viral diversity being observed in bats and rodents. The closest relatives of HCV
were found in horses/donkeys (equine hepaciviruses, EHV). However, the origin of HCV
as a human pathogen is still an unsolved puzzle. Using a selection-informed evolutionary
model, we show that the common ancestor of extant HCV genotypes existed at least
3000 years ago (CI: 3192–5221 years ago), with the oldest genotypes being endemic to
Asia. EHV originated around 1100 CE (CI: 291–1640 CE). These time estimates exclude
that EHV transmission was mainly sustained by widespread veterinary practices and
suggest that HCV originated from a single zoonotic event with subsequent diversification
in human populations. We also describe a number of biologically important sites in
the major HCV genotypes that have been positively selected and indicate that drug
resistance-associated variants are significantly enriched at positively selected sites. HCV
exploits several cell-surface molecules for cell entry, but only two of these (CD81 and
OCLN) determine the species-specificity of infection. Herein evolutionary analyses do
not support a long-standing association between primates and hepaciviruses, and
signals of positive selection at CD81 were only observed in Chiroptera. No evidence
of selection was detected for OCLN in any mammalian order. These results shed light
on the origin of HCV and provide a catalog of candidate genetic modulators of HCV
phenotypic diversity.
Keywords: hepatitis C virus, equine hepacivirus, molecular dating, tMRCA, positive selection, resistance-
associated amino acid variants, CD81
INTRODUCTION
Hepatitis C virus (HCV, genus Hepacivirus, family Flaviviridae) is a hepatotropic human pathogen
with an estimated worldwide seroprevalence around 2.8% (Mohd Hanafiah et al., 2013).
The seven major HCV genotypes display remarkable antigenic variability and are classified into
several recognized subtypes (Smith et al., 2014). A small number of “epidemic” subtypes (1a, 1b,
3a, and 2a) account for the overwhelming majority of infections worldwide (Simmonds, 2013;
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Messina et al., 2015). Their spread occurred recently (in the
last 50–100 years), following the development of practices that
cause parenteral exposure (Pybus et al., 2001; Simmonds, 2013;
Jackowiak et al., 2014). The epidemic subtypes represent a small
fraction of HCV diversity. In sub-Saharan Africa and South-
East Asia, the pattern of HCV diversity is characterized by
highly divergent subtypes of the same genotype dominating
transmissions across geographically contiguous areas (“endemic”
transmission) (Simmonds, 2013; Jackowiak et al., 2014).
Hepaciviruses have been identified in several domestic and
wild mammals, the largest viral diversity being observed in bats
and rodents (Kapoor et al., 2011, 2013; Burbelo et al., 2012;
Drexler et al., 2013; Quan et al., 2013; Corman et al., 2015; Scheel
et al., 2015; Walter et al., 2016; Van Nguyen et al., 2018). The
closest relatives of HCV were found in horses/donkeys and dogs
(equine and canine hepaciviruses, EHV, and CHV) (Pybus and
Gray, 2013; Pybus and Theze, 2016), but the origin of HCV
as a human pathogen is still an unsolved puzzle. Some authors
envisaged the possibility that HCV evolved from a horse-to-
human transmission event (Pfaender et al., 2014; Scheel et al.,
2015), others suggested that HCV originated in relatively recent
times from one or multiple cross-species transmission events
from a still to be defined species (Pybus and Gray, 2013; Scheel
et al., 2015; Pybus and Theze, 2016). However, its strict species-
specificity, as well as the ability of HCV to persist lifelong
in humans, led to the alternative hypothesis whereby HCV-
related viruses have been infecting humans and other primates
throughout their evolutionary history (Simmonds, 2013; Scheel
et al., 2015).
Another open question is whether HCV genotypes differ in
terms of transmissibility or disease outcome. Conversely, the viral
genotype is known to represent a predictive factor for antiviral
treatment success. Treatment with pegylated interferon and
ribavirin (pegIFN/RBV) is less likely to be successful in patients
infected with genotypes 1 and 4 compared to those infected with
genotypes 2 and 3 (Bartenschlager et al., 2013), and variants
at the human IFNL3/IFNL4 locus were reproducibly associated
with pegIFN/RBV treatment outcome (O’Brien et al., 2014).
Interestingly, the same polymorphisms are strongly associated
with spontaneous HCV clearance (O’Brien et al., 2014). Recently,
direct-acting antivirals (DAAs) have greatly improved the efficacy
of treatment strategies for HCV. However, DAAs have limited
pan-genotypic activity and tend to select for resistance-associated
amino acid variants (RAVs) (Lontok et al., 2015). Most RAVs
naturally occur in treatment-naive patients and in some instances
RAV prevalence differs among genotypes or subtypes (Rai and
Deval, 2011; Bartenschlager et al., 2013; Lontok et al., 2015;
Cannalire et al., 2016; Chen et al., 2016; Patino-Galindo et al.,
2016).
Herein, we apply an evolutionary approach to shed light into
HCV origin, to analyze its adaptation to human populations,
and to verify if the emergence of drug-resistant variants is a
result of positive selection. We also analyzed the most important
cell-surface molecules that mediate HCV cell entry to determine
whether HCV or related hepaciviruses exerted a selective pressure
on these receptors and whether selection was particularly strong
in specific mammalian orders or superorders.
MATERIALS AND METHODS
Evolutionary Analysis of HCV Receptors
Coding sequences for mammalian OCLN, CD81, CLDN1, and
SCARB1 (encoding SRB1) were retrieved from the NCBI1
database. A list of species is available in the Supplementary
Table S1. DNA alignments were performed with the RevTrans 2.0
utility2, MAFFT v6.240 as an aligner) (Wernersson and Pedersen,
2003), which uses the protein sequence alignment as a scaffold
for constructing the corresponding DNA multiple alignment.
All alignments were screened for the presence of recombination
using Genetic Algorithm Recombination Detection (GARD)
(Kosakovsky Pond et al., 2006) and two methods (RDP
and GENECONV) (Sawyer, 1989; Martin and Rybicki, 2000)
implemented in the RDP4 program (Martin et al., 2017). RDP
and GENECONV were selected because they showed good power
in previous simulation analyses (Posada and Crandall, 2001; Bay
and Bielawski, 2011) and only breakpoints identified by both
methods were accepted. The cutoff p-value was set to 0.01 in both
GARD and RDP4. No method detected recombination in any
alignment.
After running a codon model selection analysis in HYPHY
(Delport et al., 2010), gene trees were generated by maximum-
likelihood using phyML with the approximate likelihood-ratio
test (aLRT) method (Guindon et al., 2010).
To search for positive selection, we applied the site models
implemented in PAML (Yang, 2007). Specifically, a model (M8,
positive selection model) that allows a class of sites to evolve
with dN/dS > 1 was compared to two models (M7 and M8a,
neutral models) that do not allow dN/dS > 1 (Yang, 2007).
Positively selected sites were identified through Bayes Empirical
Bayes (BEB) analysis (Anisimova et al., 2002; Yang et al., 2005)
from model M8 (with a posterior probability cutoff of 0.90)
and through Mixed Effects Model of Evolution (MEME), with
a default p-value cutoff of 0.10) (Murrell et al., 2012). Only
sites detected by both methods were considered as positively
selected. Very similar results were obtained using the gene tree
obtained with PhyML or the species tree as inputs for PAML
analysis.
Time Estimates
To estimate the time to the most common ancestor (tMRCA) of
the 7 HCV genotypes, we used alignments of 67 HCV sequences
with known isolation dates (Supplementary Table S2). Viral
sequences were retrieved from the NCBI1 database. We used
PRANK (Loytynoja and Goldman, 2005) to generate multiple
sequence alignments and GUIDANCE (Sela et al., 2015) for
filtering unreliably aligned codons (we masked codons with a
score< 0.90), as suggested (Privman et al., 2012).
The NS5B region we used for dating is non-recombining,
as assessed by GARD and RDP4 analyses of the entire non-
structural portion of the genome. This region was selected
because it is one of the most conserved across HCV genotypes
(Kapoor et al., 2011) and required very minor filtering.
1http://www.ncbi.nlm.nih.gov/
2http://www.cbs.dtu.dk/services/RevTrans/
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The tMRCA of EHV/CHV was estimated on a phylogeny of
18 sequences with complete coding sequence information: 17
EHV isolated from horses or donkeys and 1 CHV (Kapoor et al.,
2011; Burbelo et al., 2012; Walter et al., 2016) (Supplementary
Table S3). GUIDANCE detected no uncertainty in the alignments
(all codons had a score> 0.9) and GARD detected a breakpoint at
position 6729. In good agreement, RDP4 detected a breakpoint at
position 6747. The terminal 2145 nucleotides were thus removed
and the resulting alignment was used for tree construction and
tMRCA estimate.
To determine whether there was sufficient temporal structure
in the NS5B and EHV phylogenies to estimate divergence times,
we calculate the correlation coefficients (r) of regressions of root-
to-tip genetic distances against sequence sampling times (Murray
et al., 2016). A method that minimizes the residual mean squares
of the models, rather than one that maximizes r2, was applied, as
suggested (Murray et al., 2016). The p-values were calculated by
performing 1,000 clustered permutations of the sampling dates
(Duchene et al., 2015; Murray et al., 2016). Evidence for temporal
structure was obtained for both phylogenies (NS5B: r = 0.25,
r2 = 0.0625, p-value = 0.024; EHV: r = 0.35, r2 = 0.1225,
p-value= 0.013).
The action of saturation and purifying selection can
underestimate the tMRCA, and selection-informed models can
improve branch length estimation (Wertheim and Kosakovsky
Pond, 2011; Wertheim et al., 2013, 2014). We thus applied a
branch-site test (aBS-REL, adaptive branch-site random effects
likelihood) (Smith et al., 2015) to estimate branch lengths while
taking into account the effect of different selective pressures
among lineages in the phylogeny. Previous works showed that,
in the presence of saturation and selection, aBS-REL estimates
branch lengths more reliably than other commonly used models
such as the general time-reversible substitution model with a
four-bin gamma rate distribution (GTR+04) (Wertheim and
Kosakovsky Pond, 2011; Wertheim et al., 2013).
Estimate of divergence times was performed by a penalized-
likelihood (PL) method implemented in r8s (Sanderson, 2003),
using the aBS-REL tree as the input tree. In the case of 3 extremely
long (i.e., more than 50 substitution/site) terminal branches,
most likely resulting from low precision in point estimates of
dN/dS, MG94 branch lengths were used instead of aBS-REL
lengths to avoid biases in the tMRCA estimates. MG94 (Muse
and Gaut, 1994) is the baseline model used by aBS-REL and
it models synonymous and nonsynonymous substitution rate
variation across branches but not across sites (Muse and Gaut,
1994).
The PL method in r8s employs a smoothing parameter,
which represents how much the assumption of a molecular
clock has been relaxed. Cross-validation was run to determine
the best smoothing value for the aBS-REL tree (Sanderson,
2003).
A latin hypercube sampling scheme (LHC) was used to sample
from the aBS-REL parameter distributions so as to estimate
the confidence interval, as previously suggested (Wertheim and
Kosakovsky Pond, 2011; Wertheim et al., 2013, 2014). Briefly, 500
samples were drawn from aBS-REL analyses to estimate branch
length variance, 500 trees were generated, and then used as input
trees for r8s. The upper and the lower 95% bounds are used as
confidence intervals.
As a comparison, branch lengths were also estimated using
phyML with a maximum-likelihood approach and a GTR+04
model (Guindon et al., 2009).
Detection of Positive Selection in HCV
Genomes
We used coding sequence information for the 67 recognized
HCV subtypes (Smith et al., 2014) (Supplementary Table S2).
Viral sequences were retrieved from the NCBI1 database. As
above, we used PRANK (Loytynoja and Goldman, 2005) to
generate multiple sequence alignments and GUIDANCE (Sela
et al., 2015) for filtering unreliably aligned codons (Privman
et al., 2012). GARD (Kosakovsky Pond et al., 2006) and
the above-mentioned methods implemented in RDP4 (Sawyer,
1989; Martin and Rybicki, 2000) were used to screen for
recombination.
Phylogenetic trees were generated by maximum-likelihood
using phyML (Guindon et al., 2010) after codon model selection
in HYPHY (Delport et al., 2010).
To investigate whether episodic positive selection acted
on the internal branches of HCV phylogenies, we applied
the branch-site tests from PAML (Zhang et al., 2005) and
BUSTED (branch-site unrestricted statistical test for episodic
diversification) (Murrell et al., 2015). The p-values from
both methods were FDR-corrected to account for multiple
tested branches. A branch was considered positively selected
when statistically significant evidence was obtained with both
methods.
Positively selected sites were then identified through the BEB
analysis from model MA (with a posterior probability cutoff of
0.90) (Zhang et al., 2005) and with BUSTED (with a p-value
cutoff of 0.05) (Murrell et al., 2015). Sites were called as positively
selected if they were detected by both methods. BEB and BUSTED
were in good general agreement. On selected branches, 63.07% of
BEB sites were also detected by BUSTED and 65.68% of BUSTED
sites were also identified by BEB.
We used Single-Likelihood Ancestor Counting (SLAC) and
fixed effects likelihood (FEL) (Kosakovsky Pond and Frost,
2005) to calculate the rates of nonsynonymous and synonymous
changes at each site in the structural and in the non-structural
region alignments (analyses were performed on alignments
split on the basis of the recombination breakpoint detected
by GARD). Both SLAC and FEL estimate the probability of
selection at each site in an alignment through the dN-dS metric
(rate of nonsynonymous changes-rate of synonymous changes)
(Kosakovsky Pond and Frost, 2005). This metric is preferred over
the conventional dN/dS ratio as this latter is rendered to infinite
for dS values equal to 0.
Although SLAC and FEL use different methodologies to
estimate substitution rates (Kosakovsky Pond and Frost, 2005),
they yielded very similar results (for all sites in the HCV genome,
Spearman’s correlation coefficient = 0.73, p-value < 10−16).
SLAC and FEL were used to estimate the evolutionary rate at RAV
vs. non-RAV positions. The dN-dS statistics was also exploited to
provide an overall view of HCV genome evolution. In this case,
Frontiers in Microbiology | www.frontiersin.org 3 May 2018 | Volume 9 | Article 854
fmicb-09-00854 April 27, 2018 Time: 16:14 # 4
Forni et al. HCV Origin and Evolution
only SLAC results are shown (those obtained with FEL were very
similar).
RAV Analysis
A total of 127 RAVs in NS3, NS4B, NS5A, and NS5B were
included in the study (Supplementary Table S4). RAVs were
obtained by merging six recently compiled lists of naturally
occurring variants associated with DAA resistance (Rai and
Deval, 2011; Bartenschlager et al., 2013; Lontok et al., 2015;
Cannalire et al., 2016; Chen et al., 2016; Patino-Galindo et al.,
2016). Specifically, a list of positions where RAVs have been
reported was compiled, irrespective of the viral genotype carrying
the RAV. For statistical analysis, six RAVs that occur at codons
pruned from the alignment by GUIDANCE were removed. The
overall probability of RAV occurrence was calculated over the
number of non-pruned codons in NS3, NS4B, NS5A, and NS5B
(total length= 1877 codons).
Protein 3D Structures and Docking
For the NS5A-OAS1 docking, the crystal structure of the NS5A
domain I of a subtype 1b strain (PDB: 1ZH1) and the structure
of human OAS1 (PDB: 4IG8) were obtained from the Protein
Data Bank (PDB) (Tellinghuisen et al., 2005; Donovan et al.,
2013). The 1b subtype was used in the original study describing
interaction between OAS1 and NS5A (Taguchi et al., 2004).
Two docking methods were applied and their results compared
for consistency. Specifically, we used the PatchDock server
(Schneidman-Duhovny et al., 2005) and imposed that the F37
residue in NS5A is located at the binding interface, as described
(Taguchi et al., 2004). We next used ClusPro (Comeau et al.,
2004; Kozakov et al., 2017) without any assumption on the
residues involved in binding. The best models from ClusPro and
Patchdock were superimposed and revealed an almost identical
binding pose. We next checked that the two OAS1 regions
necessary for NS5A binding (Taguchi et al., 2004) were located
at the interface: one of these two regions (amino acids 235-275)
defines most of the contact area in the models. Overall, these
observations indicate that the binding interaction pose obtained
with the two docking methods is reliable.
The C19 sphingomyelin ligand structure was prepared for
simulation using the LigPrep module of Maestro (Schrodinger
Release, 2016-4: Maestro Schrodinger, LLC, New York, NY,
United States, 2016) to determine the 3D structure and ionization
states at pH 7.0 ± 0.2. The NS5B structure of a subtype 1b
strain (PDB ID: 4MK7 chain A) was processed with Protein
Preparation Wizard module of Maestro to remove crystal
water molecules, add hydrogen atoms, assign bond orders, and
optimize the orientation of hydroxyl groups. Docking simulation
was carried out with IFD protocol (Sherman et al., 2006) in
Extra Precision mode. The receptor grid was generated around
the Sphingomyelin Binding Domain (residues E230 to G263).
All the simulations were performed using the OPLS3 force field
(Harder et al., 2016). The docked ligand-receptor poses were
analyzed in terms of Glide Score, a scoring function that estimate
protein-ligand binding affinities (Friesner et al., 2006).
The 3D structures were rendered using PyMOL (The PyMOL
Molecular Graphics System, Version 1.8.4.0 Schrödinger, LLC).
RESULTS
CD81 Is a Target of Positive Selection in
Bats
Host receptors that mediate virus entry often evolve under
positive selection (a situation that favors amino acid replacements
over silent substitutions) to avoid viral recognition (Sironi et al.,
2015).
Four cell-surface molecules, CD81, occludin (OCLN), claudin
1 (CLDN1), and scavenger receptor class B member 1 (SRB1),
are particularly important for HCV cell entry, although only
CD81 and OCLN determine the species-specificity of infection
(Bartenschlager et al., 2013; Lindenbach and Rice, 2013). We thus
reasoned that if primates experienced long-term interactions with
HCV or closely related hepaciviruses, signals of positive selection
should be detectable at the genes encoding HCV receptors.
Conversely, if selection is evident in other mammalian orders,
these may represent the ancestral HCV reservoirs.
We retrieved coding sequences of the four genes for
mammalian species belonging to different orders, superorders or
clades (Supplementary Table S1). Due to the hypothesized role of
bats as reservoir hosts for mammalian hepaciviruses, Chiroptera
were analyzed separately from other species in the Laurasiatheria
superorder. Evidence of positive selection was searched for using
models that allow dN/dS to vary among sites in the alignment
(Yang, 2007).
No evidence of positive selection was detected for CLDN1 and
SRB1 (Table 1). Also, selection was not detected at OCLN or
CD81 in primates (Table 1), an observation that does not support
a long-standing selective pressure exerted by hepaciviruses on
these hosts. However, positive selection was not detected for
rodents, either, although these mammals are known to host a
wide diversity of hepaciviruses (Drexler et al., 2013; Kapoor et al.,
2013; Scheel et al., 2015).
For Laurasiatherian OCLN, we detected one positively selected
site located in the extracellular loop 1, which is not directly
involved in HCV binding. Notably, evidence of positive selection
for CD81 was detected only in Chiroptera (Figure 1 and Table 1).
The five positively selected sites are located at the binding
interface with the HCV glycoprotein. Single point mutations in
the corresponding region of the human receptor were shown
to reduce or abolish the interaction with the HCV E2 protein
and/or HCV infectivity (Figure 1 and Table 1) (Drummer et al.,
2002; Bertaux and Dragic, 2006; Flint et al., 2006). Conversely,
the CD81 region required for infection of hepatocytes by
Plasmodium yoelii (a rodent parasite) sporozoites is unaffected by
selection (Figure 1) (Yalaoui et al., 2008).
The observation that the positively selected sites are involved
in HCV binding and infectivity suggests that hepaciviruses
contributed to shape the genetic diversity of CD81 in bats.
HCV Originated at Least 3000 Years Ago
Previous studies provided estimates of the time to the most
recent common ancestor (tMRCA) of HCV genotypes in a
range between ∼200 and 1000 years ago, with one single
study indicating that HCV origin may date 2000 years back
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(Smith et al., 1997; Pybus et al., 2001; Kapoor et al., 2011;
Simmonds, 2013; Li et al., 2014; Lu et al., 2014). The tMRCA
of equine/canine hepaciviruses (EHV/CHV) was estimated to be
recent, dating around 1800 CE (Pybus and Theze, 2016).
It is well known that the temporal variation in rates of
nucleotide substitutions often results in underestimation of
the age of viral lineages (Duchene et al., 2014; Aiewsakun
and Katzourakis, 2016). Purifying selection and substitution
saturation are strongly associated with temporal rate variation
(Duchene et al., 2014).
Simulations experiments indicated that “classic” models (e.g.,
GTR+04) tend to underestimate branch lengths in the presence
of purifying selection (Wertheim and Kosakovsky Pond, 2011)
and substitution saturation (Wertheim et al., 2013). Because both
phenomena are more pronounced for internal branches, length
underestimation is more severe for these branches and dating
inferences are consequently affected (Wertheim and Kosakovsky
Pond, 2011; Wertheim et al., 2013). The use of models that
allow site- and branch-specific variation in selective pressure
can improve branch length estimates in the presence of both
purifying selection and substitution saturation (Wertheim and
Kosakovsky Pond, 2011; Wertheim et al., 2013).
We thus applied the aBS-REL model (adaptive branch-
site random effects likelihood) to calculate the tMRCA of
relevant nodes in a phylogeny of 67 HCV strains (Smith
et al., 2014) (Supplementary Table S2). This approach was
previously applied to revise the dating of other RNA viruses
(Wertheim and Kosakovsky Pond, 2011; Wertheim et al., 2013).
We constructed a phylogeny for the NS5B region and we
found that only 0.7% of branches showed saturation of dS.
As expected, branch lengths estimated with aBS-REL were
generally longer than those obtained with a GTR+04 model,
and this was particularly true for internal branches (Figure 2A
and Supplementary Figure S1). Using the aBS-REL model,
we estimated the tMRCA of the seven HCV genotypes to
be 3359 years ago (95% CI: 5221–3192) (Figure 2B). The
deepest tMRCA was obtained for genotype 6 (endemic in
South-East Asia), with an origin dating at least 2000 years
ago (Figures 2B,C). The tMRCAs of genotype 3 (endemic in
South Asia) and of the ancestor of genotypes 1 and 4 (both
widespread in Central Africa) were estimated to be in the 800
BCE–700 CE range (Figures 2B,C). Results for genotype 2
(endemic in West Africa) indicated an origin around 430 years
ago (Figures 2B,C).
Horse-to-human hepaciviral transmission was hypothesized
as the origin of HCV (Pfaender et al., 2014; Scheel et al.,
2015). EHV isolates show limited divergence and high levels
of purifying selection (Simmonds, 2013; Pfaender et al., 2014).
TABLE 1 | Likelihood ratio test statistics for models of variable selective pressure among sites.
Gene Genus or clade n. species Tree
length




−21lnLa p-valueb −21lnLa p-valueb
CD81
NM_004356 Primates/Scandentia 27 1.719 2.259 0.133 0.808 0.668 6.313 (1.033)
Glires 20 2.648 1.242 0.265 1.238 0.539 6.374 (1.337)
Chiroptera 10 1.490 14.340 1.526 × 10−4 15.170 5.079 × 10−4 6.282 (3.515) T163, L174, C175,
G178, L185
Laurasiatheria∗ 32 2.982 0.147 0.701 5.302 0.071 10.175 (1.107)
Afrotheria/Xenarthra 8 1.741 0.100 0.752 0.389 0.823 4.537 (1.104)
CLDN1
NM_021101 Primates/Scandentia 26 1.15 0.001 0.977 1.050 0.591 6.169 (1)
Glires 18 2.732 5.117 1 0.004 1 0.001 (3.418)
Chiroptera 8 0.512 0.689 0.406 0.152 0.927 6.490 (3.284)
Laurasiatheria∗ 34 1.968 0.225 0.635 5.813 0.055 3.362 (1.239)
Afrotheria/Xenarthra 7 1.312 2.460 0.117 4.733 0.094 1.697 (3.284)
OCLN
NM_002538 Primates/Scandentia 27 1.596 0.130 0.719 0.0616 0.970 4.844 (1)
Glires 21 4.069 1.147 0.284 4.396 0.111 1.479 (1.067)
Chiroptera 13 1.039 1.738 0.187 2.859 0.239 1.640 (2.205)
Laurasiatheria∗ 33 3.630 5.998 0.014 9.635 0.008 0.223 (4.253) L98
Afrotheria/Xenarthra 9 1.741 0 1 0.006 0.997 0.037 (2.536)
SCARB1
NM_005505 Primates/Scandentia 27 2.118 0.286 0.593 3.155 0.207 4.652 (1.317)
Glires 18 4.270 0 1 1.231 0.540 6.413 (1)
Chiroptera 11 2.168 3.809 0.051 11.584 0.003 17.344 (1.418)
Laurasiatheria∗ 28 3.333 2.723 0.099 5.753 0.056 1.158 (2.279)
Afrotheria/Xenarthra 7 1.833 0.091 1 0.009 0.995 0.093 (2.220)
aTwice the difference of likelihood for the two models compared; bp-value of rejecting the neutral models (M8a and M7) in favor of the positive selection model (M8); c% of
sites (average dN/dS) is the estimated percentage of sites evolving under positive selection by M8 (dN/dS for these codons); ∗Laurasiatheria excluding Chiroptera.
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FIGURE 1 | Positively selected sites in CD81. The membrane topology of CD81 is shown. Positions involved in HCV binding and/or infectivity are highlighted in
yellow, both on the structure (circle) and on the protein alignment. Positively selected sites Chiroptera are indicated in red. LEL: large extracellular loop; SEL: short
extracellular loop. Positions refer to the human sequence (Accession ID: NM_004356).
We thus used the same approach described above to obtain the
tMRCA of extant EHV/CHV strains (Figure 2A) (Supplementary
Table S3), producing an estimate of 863 years ago (95% CI:
1726–377).
Positive Selection Shaped the Diversity
of HCV Genotypes
A number of studies have explored the recent selective events
that generated intra-genotype and within-host genetic diversity
(Jackowiak et al., 2014), whereas the deeper evolutionary history
of HCV has remained largely unexplored. We thus used complete
sequence information for the 67 recognized HCV subtypes
(Smith et al., 2014) to search for selective events that occurred
during the radiation of the seven genotypes.
The structural and non-structural coding regions were
analyzed separately, and the core region was excluded due to the
presence of a putative alternative reading frame (Xu et al., 2001).
We next tested for the presence of recombination using GARD
and RDP4 (see the section “Materials and Methods”). None of the
RDP4 methods detected recombination either in the structural
or in the non-structural regions. Conversely, GARD detected a
possible breakpoint at the end of NS3. The lack of consistency
among recombination detection methods is somehow expected
as these approaches have distinct performances depending
on the amount of recombination, the genetic diversity of
analyzed sequences, the tree topology, and the rate variation
among sites (Posada and Crandall, 2001; Bay and Bielawski,
2011). Because our aim was to avoid the inflation of positive
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FIGURE 2 | tMRCA estimation. (A) Comparison of branch lengths obtained using the aBS-REL and the GTR models for the NS5B abd EHV phylogenies.
(B) Timescaled phylogenetic tree estimated for 67 HCV subtypes. The scale bar below the phylogeny represents years before present. The tMRCAs of analyzed
nodes are reported in red with 95% confidence intervals. (C) Geographic distribution of HCV endemic transmissions (Simmonds, 2013).
selection inference caused by unrecognized recombination, the
alignment was split into two sub-alignments (based on the
GARD-detected breakpoint) with slightly different topologies
(Figure 3).
Evidence of episodic positive selection along the internal
branches of the phylogenies was searched for using two
different branch-site methods, which rely on different
assumptions of dN/dS variation among branches (Zhang
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FIGURE 3 | Positive selection in HCV phylogenies. Maximum-likelihood phylogenetic trees for E1/E2 region, non-structural (NS) region 1, and non-structural region
2. Branch thickness is proportional to the number of positively selected sites. Branch lengths are proportional to the number of nucleotide substitutions per site.
et al., 2005; Murrell et al., 2015). The two methods
provided evidence of positive selection on multiple branches
in the structural and non-structural region alignments
(Figure 3, Supplementary Tables S5, S6). A total of 102
sites were found to be targeted by positive selection, nine
of them selected on more than one branch (Supplementary
Table S6).
Positively Selected Sites Impinge on
Central Processes of HCV Life Cycle
Analysis of positively selected sites was performed by inspection
of literature reports describing the effect of specific mutations,
as well as by performing docking analyses. Overall, positively
selected sites could be categorized on the basis of the
functional effect they are likely to entail, as follows: cell entry,
interaction with the host immune system, and association with
membrane/lipids. The details of these sites are reported below, as
well as in Figures 4, 5.
Cell Entry
As expected, none of the positively selected sites in E2 involved
the conserved residues at the CD81 binding site (Lavie et al.,
2014). Interestingly though, a mutation at residue 216 in E1
was previously obtained through in vitro adaptation of HCV
to mouse cells (Figure 4A) (Bitzegeio et al., 2010). Specifically,
the L216F mutation (as well as two other mutations in the
hypervariable region 1, HVR1) allow infection of cells expressing
CD81 of rodent origin (Bitzegeio et al., 2010), suggesting that
HCV adaptation to new hosts does not necessarily entail changes
at the direct binding interface with CD81.
Several positively selected sites were detected in the
transmembrane (TM) regions of both E1 and E2 (Figure 4A).
A positively selected site in the E1 TM domain (residue
374) was shown to reduce the dependency on SCARB1 for
cell-to-cell spread in vitro, but increases viral susceptibility
to antibody-mediated neutralization (Catanese et al., 2013).
Interestingly, a similar phenotype was described for a T563V
mutant in the JFH1 viral background (corresponding to the
positively selected 561 site in strain H77) (Figure 4A) (Zuiani
et al., 2016). Using a site-directed saturation mutagenesis
approach, the T563V mutation was shown to confer growth
advantage in vitro via reduced dependency on SCARB1
and probably stronger binding to CD81 (Zuiani et al.,
2016).
Interaction With the Host Immune
System
Several mechanisms for HCV resistance to IFN have been
proposed. The NS5A protein displays a double-stranded RNA-
activated protein kinase R (PKR) binding site that overlaps with
the IFN sensitivity determinant (ISDR) region but includes 26
additional amino acids essential for PKR binding (Gale et al.,
1998). Two positively selected sites were detected within this
26 amino acid region (Figure 5A). Mutations at the second
selected site (position I302 in H77, corresponding to C298
in the JFH1 sequence) arise when HCV is passaged in the
presence of IFN-alpha (Perales et al., 2013). The C298I change
is positively selected on the genotypes 1/4 branch and both
genotypes are relatively resistant to IFN therapy (Jackowiak et al.,
2014).
The binding of NS5A to OAS1 also contributes to inhibition
of IFN antiviral activities (Taguchi et al., 2004). Based on
previous biochemical data (Taguchi et al., 2004), we performed
protein–protein docking of NS5A domain I and human OAS1.
Results showed that three of the positively selected sites in
NS5A domain I, positions 54, 78, and 93 are at the direct
binding interface with OAS1 (Figure 5B). Notably, besides
being described as RAVs for DAAs, substitutions at the Y93
site in the subtype 1b background occur at different frequency
depending on the host’s genotype at the IFNL3/IFNL4 locus
(Akamatsu et al., 2015; Peiffer et al., 2016). A similar trend
was observed for variants at NS5A positions 31 (not included
in the crystal), 37 (which modulates OAS1 binding) (Taguchi
et al., 2004), 52 (close to the binding interface), and 54
(a positively selected RAV close to the binding interface)
(Figure 5B) (Akamatsu et al., 2015). Interestingly, sites 93
and 54 are positively selected on the genotype 6 and 3
branches, respectively (Supplementary Table S5). Both these
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FIGURE 4 | Selected sites in HCV proteins. (A) Schematic representation of the HCV structural region. Regions that were not analyzed (i.e., core region) or filtered
due to poor alignment quality are colored in gray. The location of positively selected sites is shown and residues with known functional significance (see text and
below) are underlined. Sites are numbered based on the sequence of the H77 strain (AF009606.1). The ectodomain region of E1 contains two short regions with
sequence similarity to class II fusion peptides (Drummer et al., 2007): in vitro mutagenesis indicated that changes at positively selected residues 285, 286, and 288
abolish or reduce viral entry (Drummer et al., 2007; Li et al., 2009; Russell et al., 2009). A 12 amino acid motif in E2 (the PKR-eIF2α phosphorylation site homology
domain, PePHD) is required for PKR and PERK (PKR-like ER-resident kinase) inhibition (Taylor et al., 1999; Pavio et al., 2003). An amino acid alignment for the
PePHD domain is reported (representative HCV sequences only), with positively selected sites in red. TM: transmembrane domain. (B) Topological structure of the
NS2 and NS4B proteins. Positively selected sites are mapped (red) on the NS2 (PDB ID: 2HD0) and NS4B (PDB ID: 2LVG, 2JXF, 2KDR) protein structures. Protein
segments of unresolved structure are represented as cylinders (transmembrane domains) or dotted lines. An amino acid alignment of the second amphipathic helix
of NS2 is reported for representative strains (positively selected sites in red): mutagenesis of positively charged residues at positions 131 or 134 (depending on the
genotype) affect NS2 membrane association, protein stability, and efficient HCV polyprotein processing (Lange et al., 2014). The presence of at least one positively
charged residue at these positions is sufficient to allow proper membrane localization (Lange et al., 2014) and indeed, the two positions evolve in concert in the HCV
phylogeny with a charged residue always observed at either position 131 or 134, but never at both sites. ER: Endoplasmic reticulum.
genotypes are endemic in Asia, where the frequency of the
protective human IFNL3/IFNL4 variant (rs12979860) is highest
(Figure 5C).
Recently, a large-scale analysis of patients mostly infected with
HCV genotype 3a, identified 30 sites in the viral polyprotein
showing association with one or more HLA alleles (Ansari
et al., 2017). We found three of these sites (561 in E2, 620 in
NS3, and 48 in NS4B) to be positively selected, with site 620
in NS3 (position 1646 in the polyprotein) representing one of
the strongest association detected in the study (Ansari et al.,
2017).
Association With Membranes and Lipids
All HCV proteins are tethered to intracellular membranes
either via transmembrane domain or through amphipathic
alpha helices or both (Bartenschlager et al., 2013).
We identified several positively selected sites within
amphipathic alpha helices (Figure 4B). In the case of
NS4B, virtually all sites are located in these regions,
where several RAVs also map (Supplementary Table S4).
Among these, W43 (selected on the genotype 4 branch)
is essential for NS4B association to the membrane and
to lipid droplets (Gouttenoire et al., 2009; Tanaka et al.,
2013).
We found positively selected sites within the sphingomyelin
binding domain (SBD) of the HCV RNA polymerase (NS5B).
Binding of sphingomyelin to NS5B allows localization of the
polymerase to lipid rafts and activates the enzymatic activity in a
genotype-dependent manner (Sakamoto et al., 2005; Weng et al.,
2010). Remarkably, mutagenesis experiments indicated that the
positively selected sites 244 and 238 modulate sphingomyelin
binding and activation, respectively (Weng et al., 2010). We
thus docked a sphingomyelin molecule onto the 3D structure of
subtype 1b NS5B (Figure 5D). Docking results confirmed a salt
bridge interaction between residue 244 and the sphingomyelin
(along with residues 241, 242, and 250) and the localization
of residue 238 at the interaction surface. Moreover, analysis
of atomic distances indicated that two additional selected sites
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FIGURE 5 | NS5A/NS5B selection at the binding interface. (A) Schematic representation of the HCV NS5A protein. Regions that were filtered due to poor alignment
quality are colored in gray. The location of positively selected sites is shown and residues discussed in the text are underlined. Positions 68 and 69 are also
underlined, as a single lysine insertion between these two sites strongly increases viral replication (Pflugheber et al., 2002). (B) Superimposition of NS5A-OAS1
binding pose obtained using two different docking programs. For clarity, one OAS1 molecule is shown (green); the binding poses of the NS5A dimer obtained with
ClusPro (yellow) and PatchDock (light orange) are shown. The F37 residue, known to modulate NS5A binding to OAS1, is marked in orange. Positively selected sites
are in red and labeled based on the sequence of H77. OAS1 regions that are essential for NS5A binding are in dark green. (C) World map showing rs12979860
allele frequency in human populations (data from https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/ and https://alfred.med.yale.edu/alfred/high
ThroughPut.asp). (D) Docking pose of NS5B (PDB ID: 4MK7, white) with sphingomyelin (green). Positively selected sites are colored in red and labeled when located
at the NS5B-sphingomyelin binding interface. (E) Ligand interaction diagram of best docked pose of NS5B-sphingomyelin. Residues within a 6Å distance and
hydrogen bonds are shown (see legend).
(231 and 73) are likely involved in the binding of sphingomyelin
(Figure 5E).
RAVs Show Significant Overlap With
Positively Selected Sites
A recent analysis indicated that several RAVs occurred de novo
on external branches of HCV phylogenies, although a minority
appeared on internal branches, indicating a common origin
in multiple strains (Patino-Galindo et al., 2016). However, the
evolutionary history of RAVs has remained a poorly investigated
issue.
Up to now, direct-acting antivirals (DAAs) have been
developed to inhibit the function of the NS3, NS4B, NS5A, and
NS5B proteins. To obtain a codon-wise measure of selective
pressure acting on these proteins across the HCV phylogeny,
we calculated dN-dS at each site. Comparison of RAV and
non-RAV sites revealed no statistically significant difference in
dN-dS calculated with either SLAC (Wilcoxon’s rank-sum test
p-value= 0.19) or FEL (Wilcoxon’s rank-sum test p-value= 0.59)
(Figure 6A). This suggests that RAVs do not originate and
are not maintained in viral populations as a result of relaxed
selective constraints. This overall trend does not imply that all
RAV sites evolve at the same rate. Thus, we tested whether
positions where RAVs occur are more likely to diversify through
the action of natural selection. Nine RAV positions coincided
with positively selected sites, a number higher than expected
by chance (Binomial test, p-value = 0.012) (Supplementary
Table S4). Moreover, three of these RAV positions were
targeted by positive selection on two distinct branches of the
phylogeny, a situation observed for only 8.8% of selected sites
(Figure 6A).
To gain a comprehensive view of the action of selection, we
plotted dN-dS along the HCV genome and we superimposed the
location of positively selected sites and of RAVS (Figure 6B).
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FIGURE 6 | RAV evolution. (A) Standard box-and-whisker plot representation (thick line: median; box: quartiles; whiskers: 1.5 × interquartile range) of dN-dS (SLAC
method) at RAV and non-RAV positions. Positively selected RAVs are shown with two flanking amino acid residues for few representative HCV subtypes. RAVs are in
red depending on the branch they are selected on. (B) Plot of dN-dS (SLAC method) across the HCV genome (with the exclusion of the core region). Positively
selected sites are denoted with a red dot and RAVs with a blue circle. The dashed line represents the median value. Positions refer to the H77 strain (AF009606.1).
In agreement with a previous work that analyzed conservation
and selection in HCV-1a and HCV-1b genomes (Patino-Galindo
and Gonzalez-Candelas, 2017), dN-dS tended to be higher in
the E1 and E2 regions, compared to the non-structural portions.
A non-negligible fraction of codons showed almost complete
conservation: about 7% displayed dS= 0 and most of these (89%)
also had dN = 0. Both RAV positions and positively selected
sites displayed variable dN-dS values. We note that this is not
unexpected for positively selected sites as they were identified
using branch-site tests and are thus not selected across the entire
HCV phylogeny.
DISCUSSION
The worldwide spread of HCV epidemic strains started recently,
in the 1930s–1940s, but the existence of genetically diverse
endemic HCV strains that circulate in specific geographic
locations implies a long-standing association of the virus with
human populations (Simmonds, 2013). Using an evolutionary
model that accounts for variation in the pressure of natural
selection across sites and branches, we show that the common
ancestor of extant HCV genotypes existed at least 3000 years ago,
with a lower bound estimate of ∼5200 years before present. The
same approach placed the origin of EHV/CHV around 1100 CE,
with a lower bound at 290 CE. Although we applied a selection-
informed approach that accounts for the effect of purifying
selection and is relatively robust in the presence of substitution
saturation (Wertheim et al., 2013), we most likely failed to fully
correct for time-dependent substitution rate variation (Ho et al.,
2015). Thus, the time of HCV and EHV/CHV origin might
be underestimated. However, these time estimates rule out the
possibility that the use of horse serum to obtain therapeutic anti-
toxins originated HCV and, more generally, seem to exclude the
hypothesis that the human virus derived from a cross-species
transmission event from horses (Pfaender et al., 2014; Scheel
et al., 2015). Nonetheless, the sampling of EHV is still sparse.
The isolation of additional EHV sequences, possibly from a wider
geographic range, may date the origin of this virus further back.
Horse domestication begun around 5000 years ago in Central
Asia (Outram et al., 2009): where EHV found to be older,
close contacts between horses and humans may have resulted in
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zoonotic cross-species transmission or in the acquisition of HCV
and EHV from a common source (possibly bat or rodent). Active
sampling of horse and donkeys worldwide will be required to
address this important point.
The time frame of HCV origin and the geographic distribution
of the endemic strains are not consistent with the possibility that
HCV dispersed with humans following the major out-of-Africa
colonization routes across the Old World (65000–45000 years
ago) (Nielsen et al., 2017). The dating we estimated for HCV
origin instead suggests that the (possible) zoonotic transmission
and subsequent spread in human populations occurred in a time-
frame when long-distance trade routes were being established.
The deepest tMRCA for HCV genotypes was obtained for
genotype 6, possibly indicating an Asian origin of extant strains.
Several historical situations may help explain the diffusion of
HCV in Asia and Africa.
Maritime trading routes across the South Chinese Sea were
already developed in the first millennium BCE (Hung et al.,
2013), and regular sea connections between South-East Asia
and India were established by 1000–500 BCE (Pearson, 2016).
More extensive human movements connecting Asia with Africa
occurred starting around ∼300 BCE as a result of Alexander the
Great expansion (336-325 BCE) and the full development of the
Silk Road (since 200 BCE), this latter comprising maritime and
land routes that reached Africa (Lawler, 2014). Around this time,
Indian slaves, mostly women, were regularly imported to Egypt
(Mark, 2002). Moreover, archaeological evidences suggest that
trade circuits connected the East Coast of Africa with South Asia
in the first millennium CE3.
Whereas these represent possible transmission routes, it
remains unclear how, in a time when parenteral exposure
was limited, HCV spread and was maintained in human
populations. Vertical transmission of HCV is rare and sexual
contact is also thought to be a scarcely efficient route for
HCV dissemination. It was thus proposed that cultural practices
(e.g., circumcision, tattooing, or acupunture) (Shepard et al.,
2005; Simmonds, 2013) or natural routes such as arthropod
biting (Pybus et al., 2007) might account for endemic HCV
transmission. This issue is not addressed by the analyses herein.
However, our time estimates place the origin of EHV in a
time frame when invasive veterinary procedures and parenteral
exposure were most likely rare. Although we cannot exclude that
some forms of human intervention (e.g., the use of spurs and
animal housing in crowded stables) facilitated viral transmission,
natural routes are likely to account for the spread of EHV.
Whether the same mechanisms are responsible for the endemic
transmission of HCV and of EHV remains an open question.
In this respect, we note that sexually transmitted infections
(STIs) that disrupt mucosal integrity have been implicated in
increased sexual transmission of HCV, at least in high-risk
groups (Chan et al., 2016). STIs have probably been common
throughout human history and several such diseases are known
in horses (Dobson and Carper, 1996; Samper and Tibary,
2006). The association between HCV sexual transmission and
specific STIs might help explain the geographic distribution
3http://www.sealinksproject.com/
of endemic HCV strains. For instance, lymphogranuloma
venereum and granuloma inguinale are confined to tropical
and subtropical regions (Richens, 2006; White, 2009) and
their presence may have facilitated the maintenance and
diversification of endemic HCV strains in these areas. Although
the present-day distribution of these STIs may not necessarily
reflect the historical prevalence of the causative bacteria, the
hypothesis of STI-facilitated HCV transmission warrants further
consideration.
Although we found that the tMRCA for HCV is greater than
the previously inferred time ranges (Smith et al., 1997; Pybus
et al., 2001; Kapoor et al., 2011; Simmonds, 2013; Li et al.,
2014; Lu et al., 2014), HCV can be thought of as a recently
emerged pathogen, largely postdating the origin of our species.
This observation, as well as the presently limited evidence of
hepacivirus infection in non-human primates, does not support
a long-standing association between these viruses and primates
(Simmonds, 2013; Scheel et al., 2015). The absence of selection
signatures at primate CD81 and OCLN, the two molecules
that determine the species-specificity of HCV infection, further
supports this view. However, as noted above, we also failed to
detect positive selection for HCV receptors in glires, even though
the wide variety of rodent hepaciviruses suggests that these
mammals have been infected by hepaciviruses for a long time
(Drexler et al., 2013; Kapoor et al., 2013; Scheel et al., 2015). Thus,
results obtained for the HCV receptors are clearly not conclusive
and should be regarded as preliminary. Indeed, the power of
the positive selection tests depends not only on the strength
of selection, but also on the number and divergence of the
analyzed sequences (Anisimova et al., 2001, 2002). Considering
these two parameters, we have most likely a power lower than
80% although accuracy is higher than 90% (Anisimova et al.,
2001, 2002). Given this premise, it is nonetheless interesting that
the only mammalian order showing evidence of selection at CD81
was Chiroptera, which host a wide diversity of hepaciviruses
(Kapoor et al., 2011, 2013; Drexler et al., 2013; Quan et al.,
2013; Corman et al., 2015; Scheel et al., 2015; Walter et al.,
2016).
Known bat hepaciviruses share very little similarity to the
HCV E2 protein, and this also applies to the E2 regions involved
in CD81 binding. This raises the possibility that these animal
viruses engage cellular receptors distinct from CD81, although
previous studies on coronaviruses showed that the same region
of the cellular receptor can be bound by viruses that share
little sequence or structural similarity in their glycoprotein
receptor binding domains (Forni et al., 2017). Also, recent
studies have indicated that HCV adaptation to the usage of
rodent CD81 molecules is not necessarily paralleled by changes
at the direct binding interface (Bitzegeio et al., 2010). Thus, the
receptor preferences of non-human hepaciviruses will require
experimental investigation. Nonetheless, the observation that
the CD81 positively selected sites in Chiroptera are located
in a small region that corresponds to the E2 binding site is
consistent with the view that CD81-binding hepaciviruses have
been infecting bats for a long time. However, we note that
CD81 was also shown to interact with other pathogens. For
instance, CD81 is required for human Plasmodium falciparum
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and rodent Plasmodium yoelii sporozoite hepatocyte infection
(Silvie et al., 2003). Even though the protein region necessary and
sufficient for P. yoelii infection is distinct from that involved in
HCV binding (Yalaoui et al., 2008), we cannot exclude that bat-
infecting Plasmodium parasites (Schaer et al., 2013) bind different
regions of CD81. Also, CD81 was shown to be important for
influenza virus infection (He et al., 2013), but the molecular
details of the interaction with this virus are unknown. Thus,
we cannot rule out the possibility that pathogens other than
hepaciviruses were responsible for the selection signatures we
detected at CD81 in bats.
Zoonotic events are commonly associated with bursts of
positive selection whereby the pathogen adapts to successfully
infect and be transmitted in a new species (Longdon et al.,
2014). A common trade-off of the adaptation to new hosts
is the loss or reduction of infectivity in the original host
(Longdon et al., 2014). Indeed, HCV infection is now restricted to
humans (and to experimentally infected chimpanzees). Because
the ancestor of HCV has not been identified, knowledge of
the molecular events that allowed HCV adaptation to humans
remains elusive. We identified several positively selected sites
in the E1 and E2 regions and some of these were shown
to modulate the viral requirement of specific cellular factors
(i.e., CD81 and SCARB1). Whereas these changes are not
expected to represent specific adaptations to the human host,
they may confer a selective advantage by increasing viral
titers or cell-to-cell spread, a process possibly implicated
in the establishment of a persistent infection (Ding et al.,
2014).
An interesting possibility is that, during its spread in Asia and
Africa, HCV has adapted in response to the genetic background
of distinct human populations, as expected given the distinctive
geographic localization of viral genotypes for most of their
evolutionary history. A paradigmatic example of this is the
distribution of the IFNL3/IFNL4 polymorphism most strongly
associated with spontaneous clearance of HCV: the frequency of
the protective genotype differs dramatically among populations
and this variant explains part of the ethnic variance in the
probability to clear HCV infection (O’Brien et al., 2014).
We identified two positively selected sites (H54 and Y93 in
NS5A) on the branches of the Asian endemic genotypes (3 and 6,
respectively). Analysis of patients infected with HCV subtype 1b
showed that substitutions at the Y93 sites and, to a lesser extent
at the H54 position, vary depending on the host IFNL3/IFNL4
genotype (Akamatsu et al., 2015; Peiffer et al., 2016). This
observation implies viral adaptation to the host depending on
IFNL3/IFNL4 allelic status. Although these findings are presently
limited to genotype 1b viruses (Akamatsu et al., 2015; Pedergnana
et al., 2016; Peiffer et al., 2016), they provide a proof of principle
for the hypothesis that human genetic diversity exerted a selective
pressure on HCV and possibly contributed to the radiation of the
seven genotypes.
Clearly, it remains to be evaluated whether changes at
positions Y93 and H54 exert their effects via modulation of OAS1
binding, as the docking analysis suggests, at least for position 93.
Alternatively, other mechanisms may be at play: a lysine insertion
between NS5A positively selected sites K68 and N69, which are
not at the binding interface with OAS1, regulates PKR and IRF-3
activity (Pflugheber et al., 2002; Sumpter et al., 2004).
In general, the positively selected sites we identified herein
represent excellent candidates for future functional studies as
they are expected to modulate viral phenotypes. For instance,
selected sites in NS5B account for genotype differences in terms
of sphingomyelin-driven polymerase activation (Sakamoto et al.,
2005; Weng et al., 2010), and the C298I change that arose in the
common ancestor of genotypes 1 and 4 may help explain the poor
response of these genotypes to IFN therapy.
Exposure to treatment cannot be regarded as the selective
force underlying the evolution of the HCV sequences analyzed
herein, as all strains derive from treatment-naive subjects. It
was recently reported that several RAVs have a recent origin
and occurred independently on distinct viral lineages (Patino-
Galindo et al., 2016). This observation is in line with the notion
that substitutions at RAV positions can reduce viral fitness
(Bartenschlager et al., 2013) and thus fail to be maintained in viral
populations or transmission clusters. Indeed, by calculating the
strength of selective pressure acting on HCV proteins targeted
by DAAs, we observed that most RAV positions are subject to a
degree of purifying selection similar to non-RAV positions. This
suggests that RAVs do not arise via relaxed selection but rather
that these positions are functionally constrained. However, we
also found that RAV positions are targeted by positive selection
more frequently than expected by chance. Variation at these sites
must therefore be adaptive for the virus, raising the possibility
that DAA treatment further selects for DAA-resistant viruses
with high fitness. This pattern contrasts with observations in
HIV-1 infection, as positive selection at codons that confer drug
resistance was only observed in patients receiving antiretroviral
therapy (de S Leal et al., 2004). We note, though, that most RAVs
investigated here were described for genotype 1 and might confer
little or no drug resistance to other HCV genotypes. Conversely,
most RAV sites were positively selected on branches different
than that leading to genotype 1. Their functional relevance will
thus need to be analyzed further.
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